Cytokinetics, Inc. (CYTK) Posts Q2 EPS Loss of $0.23, Well Below Expectations
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $72.72 -1.66%
EPS Growth %: +43.1%
Financial Fact:
Research and development revenues from related parties: 5.57M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +43.1%
Financial Fact:
Research and development revenues from related parties: 5.57M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Cytokinetics, Inc. (NASDAQ: CYTK) reported Q2 EPS of ($0.23), $0.12 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $1.05 million versus the consensus estimate of $6.38 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Truist Securities Reiterates Buy Rating on Cytokinetics (CYTK)
- Torrid Holdings Inc. (CURV) Tops Q2 EPS by 8c; Offers Guidance
- John Wiley & Sons, Inc. (WLYB) Misses Q1 EPS by 2c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
